Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-11-07
2006-11-07
Jones, Dwayne C. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S233800, C514S252010, C514S252160, C514S252170, C514S345000, C514S351000, C514S620000, C514S654000
Reexamination Certificate
active
07132430
ABSTRACT:
Methods for treating cardiovascular and related diseases such as arrhythmia are described. The methods are directed to concurrently administering a compound such as pyridoxal-5′-phosphate, pyridoxamine, pyridoxal, or a 3-acylated pyridoxal analogue with a therapeutic cardiovascular compound.
REFERENCES:
patent: 2904551 (1959-09-01), Pollak
patent: 3206463 (1965-09-01), Baetz
patent: 3282778 (1966-11-01), Lobel
patent: 3910921 (1975-10-01), Esanu
patent: 3987177 (1976-10-01), Giudicelli et al.
patent: 4032534 (1977-06-01), Chodkiewicz
patent: 4036844 (1977-07-01), Thorne et al.
patent: 4053607 (1977-10-01), Thorne et al.
patent: 4137316 (1979-01-01), Esanu
patent: 4167562 (1979-09-01), Evers
patent: 4361570 (1982-11-01), Fici
patent: 4369172 (1983-01-01), Schor et al.
patent: 4374841 (1983-02-01), Descamps et al.
patent: 4515771 (1985-05-01), Fine
patent: 4567179 (1986-01-01), Lombardino
patent: 4569938 (1986-02-01), Esanu
patent: 4569939 (1986-02-01), Esanu
patent: 4581363 (1986-04-01), Esanu
patent: 4605741 (1986-08-01), Zagnoli et al.
patent: 4730042 (1988-03-01), Hege et al.
patent: 4735950 (1988-04-01), Esanu
patent: 4735956 (1988-04-01), Baldwin et al.
patent: 4837239 (1989-06-01), Benjamin et al.
patent: 4843071 (1989-06-01), Hohenwarter
patent: 4962121 (1990-10-01), Hamberger et al.
patent: 5001115 (1991-03-01), Sloan
patent: 5053396 (1991-10-01), Blass
patent: 5118505 (1992-06-01), Koltringer
patent: 5130324 (1992-07-01), Ulrich et al.
patent: 5132115 (1992-07-01), Wolter et al.
patent: 5210083 (1993-05-01), Pfirrmann
patent: 5213813 (1993-05-01), Kornecki et al.
patent: 5254557 (1993-10-01), Buckle et al.
patent: 5254572 (1993-10-01), Serfontein
patent: 5272165 (1993-12-01), Ulrich et al.
patent: 5278154 (1994-01-01), Lacoste et al.
patent: 5288498 (1994-02-01), Stanley et al.
patent: 5288716 (1994-02-01), Speck
patent: 5326757 (1994-07-01), Demopoulos
patent: 5328453 (1994-07-01), Sibalis
patent: 5372999 (1994-12-01), Schneider et al.
patent: 5385937 (1995-01-01), Stamler et al.
patent: 5420112 (1995-05-01), Lewis et al.
patent: 5441972 (1995-08-01), Ogata et al.
patent: 5504090 (1996-04-01), Neely
patent: 5563126 (1996-10-01), Allen et al.
patent: 5569459 (1996-10-01), Shlyankevich
patent: 5569648 (1996-10-01), Lewis et al.
patent: 5631271 (1997-05-01), Serfontein
patent: 5633228 (1997-05-01), Lewis et al.
patent: 5648335 (1997-07-01), Lewis et al.
patent: 5668117 (1997-09-01), Shapiro
patent: 5728684 (1998-03-01), Cheng et al.
patent: 5733884 (1998-03-01), Barbul et al.
patent: 5733916 (1998-03-01), Neely
patent: 5770215 (1998-06-01), Moshyedi
patent: 5795873 (1998-08-01), Allen
patent: 5804163 (1998-09-01), Gibby et al.
patent: 5804594 (1998-09-01), Murad
patent: 5833998 (1998-11-01), Biedermann et al.
patent: 5834446 (1998-11-01), Dow et al.
patent: 5840685 (1998-11-01), Fujii et al.
patent: 5847008 (1998-12-01), Doebber et al.
patent: 5858017 (1999-01-01), Demopulos et al.
patent: 5859051 (1999-01-01), Adams et al.
patent: 5874420 (1999-02-01), Pelleg
patent: 5874443 (1999-02-01), Kiely et al.
patent: 5888514 (1999-03-01), Weisman
patent: 6043259 (2000-03-01), Dhalla et al.
patent: 6066659 (2000-05-01), Speck
patent: 6339085 (2002-01-01), Haque
patent: 6890943 (2005-05-01), Haque
patent: 831350 (1976-01-01), None
patent: 863754 (1978-05-01), None
patent: 2 123 935 (1994-12-01), None
patent: 561183 (1975-04-01), None
patent: 1 958 226 (1970-05-01), None
patent: 24 61 742 (1976-07-01), None
patent: 28 45 484 (1978-11-01), None
patent: 37 05 549 (1988-09-01), None
patent: 43 44 751 (1995-06-01), None
patent: 0 121 036 (1984-10-01), None
patent: 0 144 051 (1985-06-01), None
patent: 0 270 026 (1987-11-01), None
patent: 0 270 026 (1988-06-01), None
patent: 0 416 248 (1991-03-01), None
patent: 0 891 719 (1999-01-01), None
patent: 846376 (1941-03-01), None
patent: 1 323 941 (1963-12-01), None
patent: 5552 (1967-12-01), None
patent: 5801 (1968-03-01), None
patent: 6453 (1968-12-01), None
patent: 1 579 544 (1969-08-01), None
patent: 2034539 (1970-12-01), None
patent: 2 101 010 (1972-03-01), None
patent: 2255883 (1975-07-01), None
patent: 2428640 (1980-01-01), None
patent: 2 641 189 (1990-07-01), None
patent: 1 013 939 (1965-12-01), None
patent: 1 201 014 (1970-08-01), None
patent: 1 297 080 (1972-11-01), None
patent: 1 360 536 (1974-07-01), None
patent: 1 493 993 (1977-12-01), None
patent: 2 254 556 (1992-10-01), None
patent: 48-21959 (1973-07-01), None
patent: 54-17130 (1979-02-01), None
patent: WO 83/00085 (1983-01-01), None
patent: WO 91/19500 (1991-12-01), None
patent: WO 94/18965 (1994-09-01), None
patent: WO 98/19690 (1998-05-01), None
patent: WO 99/03365 (1999-01-01), None
patent: WO 99/53928 (1999-10-01), None
patent: WO 00/53606 (2000-09-01), None
patent: WO 02/36109 (2002-05-01), None
Mulvaney, D. A. et al. of Cardiovascular Research, vol. 13, No. 9, pp. 506-513, 1979. Abstract.
Aybak, M. et al., “Effect of Oral Pyridoxine Hydrochloride Supplementation on Arterial Blood Pressure in Patients with Essential Hypertension”,Arzneim.-Forsch./Drug Res. 45 (11), pp. 1271-1273, Nr. 12 (1995).
“B Vitamins May Cut Heart Disease Risk”,Harvard Health Letter, 1 page (1998).
Baliga, B. et al., “Hyperhomocysteinemia in Type 2 Diabetes Mellitus: Cardiovascular Risk Factors and Effect of Treatment with Folic Acid and Pyridoxine”,Endocrine Practice, vol. 6, No. 6, pp. 435-441 (Nov./Dec. 2000).
Barrett, S., “Homocysteine: A Cardiovascular Risk Factor Worth Considering”, http://www.quackwatch.com/03HealthPromotion/homocysteine.html, 2 pages (© 1997).
Berger, A.R. et al., “Dose response, coasting, and differential fiber vulnerability in human toxic neuropathy: A prospective study of pyridoxine neurotoxicty”,Neurology, vol. 42, No. 7, pp. 1367-1370 (Jul. 1992).
Bernstein, A., “Vitamin B6in Clinical Neurology”,Annals of New York Academy of Sciences, vol. 585, pp. 250-260 (1990).
Bhagavan, H. et al., “Effects of Postweanling Pyridoxine Deficiency on Growth and Concentration of the Coenzyme Pyridoxal-5′-phosphate in Heart, Kidneys, Lungs, and Adrenals in Rats”,Pediat. Res., vol. 10, pp. 730-732 (1976).
Bode, W. et al., “Pyridoxal-5′-Phosphate and Pyridoxal Biokinetics in Male Wistar Rats Fed Graded Levels of Vitamin B-6”,J. Nutr., vol. 121, No. 11, pp. 1738-1745 (Nov. 1991).
Chasan-Taber, L. et al., “A Prospective Study of Folate and Vitamin B6and Risk of Myocardial Infarction in the US Physicians”,Journal of the American College of Nutrition, vol. 15, No. 2, pp. 136-143 (Apr. 1996).
Cho, Y. et al., “In Vivo Evidence for a Vitamin B-6 Requirement in Carnitine Synthesis”,J. Nutr., vol. 120, pp. 258-265 (1990).
“Computer Generated Search Reports”, 70 pages (May 1999).
Dakshinamurti, K. et al., Hypertension, calcium channel and pyridoxine (vitamin B6), Abstract to Molecular and Cellular Biochemistry, vol. 188, No. 1-2, pp. 137-148 (Nov. 1998).
Ellis, J. et al., “Prevention of Myocardial Infarction by Vitamin B6”,Res. Commun. Molec. Pathol. Pharmacol., vol. 89, No. 2, pp. 208-220 (Aug. 1995).
Folsom, A. et al., “Clinical Investigation and Reports: Prospective Study of Coronary Heart Disease Incidence in Relation to Fasting Total Homocysteine, Related Genetic Polymorphisms, and B Vitamins: The Atherosclerosis Risk in Communities (ARIC) Study”,Circulation, vol. 98, pp. 204-210 (Jul. 21, 1998).
Folsom, Aaron R. et al., “Prospective Study of Coronary Heart Disease Incidence in Relation to Fasting Total Homocysteine, Related Genetic Polymorphisms, and B Vitamins”,The Atherosclerosis Risk in Communities(ARIC)Study, pp. 204-210, Dec. 15, 1997.
Fragley, M. et al., “Effect of Pyridoxine and Tryptophan, Alone and Combined, on the Development of Deoxycorticosterone Acetate-Induced Hypertension in Rats,”Pharmacology, vol. 50, pp. 298-306 (1995).
Harada, K. et al., “Studies on Vitamin B6. (IV) Behavior of Pyridoxal Acylates in the Body After Parental Administration
Haque Wasimul
Sethi Rajat
Jones Dwayne C.
Medicure International Inc.
Merchant & Gould P.C.
LandOfFree
Treatment of cardiovascular and related pathologies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of cardiovascular and related pathologies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of cardiovascular and related pathologies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3670022